The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin’s lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.本揭示案總體上係關於治療腫瘤疾病或癌症的成分及方法，所述腫瘤疾病或癌症可如神經膠質母細胞瘤及非何傑金氏淋巴瘤或其他癌症，其中對象患有晚期實體腫瘤，所述成分及方法包含溴結構域及額外末端蛋白質(BET)抑制劑及至少一種化學治療劑的組合物，或投與溴結構域及額外末端蛋白質(BET)抑制劑及至少一種化學治療劑的組合物，該至少一種化學治療劑不直接抑制BET。該BET抑制劑/化學治療劑的組合，或組合療法可產生協同作用，從而與單獨投與該BET抑制劑或該化學治療劑之任一者相比，增加該癌症治療之有效性。
